Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved..
The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Cell reports - 31(2020), 9 vom: 02. Juni, Seite 107725 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lv, Huibin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 08.02.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2020.107725 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320619370 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320619370 | ||
| 003 | DE-627 | ||
| 005 | 20231226202515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2020.107725 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320619370 | ||
| 035 | |a (NLM)33500101 | ||
| 035 | |a (PII)S2211-1247(20)30702-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lv, Huibin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antigens |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 700 | 1 | |a Wu, Nicholas C |e verfasserin |4 aut | |
| 700 | 1 | |a Tsang, Owen Tak-Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Perera, Ranawaka A P M |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Wai Shing |e verfasserin |4 aut | |
| 700 | 1 | |a So, Ray T Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Jacky Man Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Yip, Garrick K |e verfasserin |4 aut | |
| 700 | 1 | |a Chik, Thomas Shiu Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yiquan |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Chris Yau Chung |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yihan |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Wilson W |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jincun |e verfasserin |4 aut | |
| 700 | 1 | |a Poon, Leo L M |e verfasserin |4 aut | |
| 700 | 1 | |a Peiris, J S Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Ian A |e verfasserin |4 aut | |
| 700 | 1 | |a Mok, Chris K P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 31(2020), 9 vom: 02. Juni, Seite 107725 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2020 |g number:9 |g day:02 |g month:06 |g pages:107725 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2020.107725 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2020 |e 9 |b 02 |c 06 |h 107725 | ||